Skip to main content
Livermore
Livermore
ZHEN

Affinity Asset Advisors, LLC

SEC CIK
0001773195
Latest filing
Aug 13, 2026

Holdings in Q1 2022

Holdings as of Mar 31, 2022, filed May 13, 2022. Long positions only; changes compare share counts with Q4 2021.

Institution overview
Positions
48
+2 vs. Q4 2021
Portfolio value
$252.2M
+$17.8M (+7.6%) vs. Q4 2021
Filed
May 13, 2022
SEC
Holdings of Affinity Asset Advisors, LLC in Q1 2022
SecurityClassSharesValue% of portfolioShare changeActionHistory
Medicus Sciences AcquisitionG5960S124*W EXP 02/12/20233,333$14.0K<0.1%00.0%Unchanged–
Renovacor, Inc.75989E114*W EXP 99/99/99975,000$26.0K<0.1%00.0%Unchanged–
BPMCBlueprint Medicines CorpCOM1,988$127.0K0.1%+1,988NewHistory
HYPRHyperfine, Inc.COM CL A76,162$270.0K0.1%00.0%UnchangedHistory
Immatics N.V.N44445117*W EXP 07/01/202187,204$328.0K0.1%−2,796−1.5%Reduced–
CALACalithera Biosciences, Inc.COM1,000,000$404.0K0.2%+1,000,000NewHistory
CNTACentessa Pharmaceuticals plcSPONSORED ADS65,282$586.0K0.2%−353,862−84.4%ReducedHistory
CRISCuris IncCOM NEW350,000$833.0K0.3%−300,000−46.2%ReducedHistory
RCORRenovacor, Inc.COM199,490$846.0K0.3%+74,490+59.6%AddedHistory
VRDNViridian Therapeutics, Inc.COM50,000$925.0K0.4%+50,000NewHistory
KRTXKaruna Therapeutics, Inc.COM7,500$951.0K0.4%+7,500NewHistory
SNCEScience 37 Holdings, Inc.COM221,382$1.18M0.5%+71,382+47.6%AddedHistory
LIANYLianBioSPONSORED ADS325,000$1.21M0.5%+252,594+348.9%AddedHistory
Bio Green Med Solution, Inc.23254L603COM400,000$1.22M0.5%00.0%Unchanged–
CNTXContext Therapeutics Inc.COM777,610$1.69M0.7%+777,610NewHistory
ACRSAclaris Therapeutics, Inc.COM100,000$1.72M0.7%−300,000−75.0%ReducedHistory
GBTGlobal Blood Therapeutics, Inc.COM70,000$2.42M1.0%+70,000NewHistory
NAUTNautilus Biotechnology, Inc.COM559,019$2.43M1.0%−490,702−46.7%ReducedHistory
XENEXenon Pharmaceuticals Inc.COM80,000$2.45M1.0%−70,500−46.8%ReducedHistory
CERECerevel Therapeutics Holdings, Inc.COM70,000$2.45M1.0%−155,000−68.9%ReducedHistory
TVTXTravere Therapeutics, Inc.COM100,000$2.58M1.0%+50,000+100.0%AddedHistory
Medicus Sciences AcquisitionG5960S108CL A SHS300,000$2.93M1.2%00.0%Unchanged–
OBIOOrchestra BioMed Holdings, Inc.ORD SHS300,000$2.97M1.2%00.0%UnchangedHistory
HZNPHorizon Therapeutics Public Ltd CoSHS30,000$3.16M1.3%+30,000NewHistory
CBAYCymaBay Therapeutics, Inc.COM1,272,244$3.96M1.6%+150,000+13.4%AddedHistory
Bellus Health Inc New07987C204COM NEW600,000$4.13M1.6%+100,000+20.0%Added–
CLDXCelldex Therapeutics, Inc.COM NEW125,000$4.26M1.7%+25,000+25.0%AddedHistory
BridgeBio Pharma, Inc.10806XAB8NOTE 2.500% 3/1–$4.38M1.7%–––
BridgeBio Pharma, Inc.10806XAD4NOTE 2.250% 2/0–$4.68M1.9%–New–
RCKTRocket Pharmaceuticals, Inc.COM300,000$4.76M1.9%+135,000+81.8%AddedHistory
VINCVincerx Pharma, Inc.COM NEW1,374,098$5.50M2.2%+238,733+21.0%AddedHistory
NSTGNS Wind Down Co., Inc.COM171,592$5.96M2.4%+171,592NewHistory
LNTHLantheus Holdings, Inc.Stock115,000$6.36M2.5%+115,000NewHistory
RPTXRepare Therapeutics Inc.COM468,905$6.68M2.6%+197,127+72.5%AddedHistory
ARYEARYA Sciences Acquisition Corp VCLASS A ORD SHS702,500$6.83M2.7%00.0%UnchangedHistory
PTGXProtagonist Therapeutics, IncCOM300,000$7.10M2.8%+58,881+24.4%AddedHistory
MDGLMadrigal Pharmaceuticals, Inc.COM75,000$7.36M2.9%+10,000+15.4%AddedHistory
Nanostring Technologies Inc63009RAD1NOTE 2.625% 5/0–$7.75M3.1%–New–
ZNTLZentalis Pharmaceuticals, Inc.COM207,500$9.57M3.8%+90,000+76.6%AddedHistory
AZNAstraZeneca PLCSPONSORED ADR160,000$10.6M4.2%+160,000NewHistory
Retrophin Inc761299AB2NOTE 2.500% 9/1–$11.5M4.6%–––
ESTAEstablishment Labs Holdings Inc.COM174,500$11.8M4.7%+97,000+125.2%AddedHistory
KDNYChinook Therapeutics, Inc.COM845,155$13.8M5.5%+290,000+52.2%AddedHistory
SWTXSpringWorks Therapeutics, Inc.COM247,000$13.9M5.5%−51,545−17.3%ReducedHistory
ASNDAscendis Pharma A/SSPONSORED ADR120,000$14.1M5.6%+120,000NewHistory
KURAKura Oncology, Inc.COM924,147$14.9M5.9%+364,147+65.0%AddedHistory
MORFMorphic Holding, Inc.COM465,654$18.7M7.4%+66,352+16.6%AddedHistory
NARIInari Medical, Inc.Stock220,000$19.9M7.9%+95,000+76.0%AddedHistory

Options (11)

Puts and calls in the same filing. Amounts are the market value of the underlying shares, which is what 13F reports.

Option positions of Affinity Asset Advisors, LLC in Q1 2022
SecurityClassPutsCalls
SPYSPDR S&P 500 ETF TrustETF$338.7M–
SWTXSpringWorks Therapeutics, Inc.COM$9.03M–
PMVPPMV Pharmaceuticals, Inc.COM–$6.61M
PTGXProtagonist Therapeutics, IncCOM$5.11M–
CRSPCRISPR Therapeutics AGNAMEN AKT–$3.45M
RLAYRelay Therapeutics, Inc.COM–$2.25M
LNTHLantheus Holdings, Inc.Stock$2.21M–
AUPHAurinia Pharmaceuticals Inc.COM–$2.17M
BEAMBeam Therapeutics Inc.COM–$1.72M
ATHXAthersys, IncCOM$858.0K–
CELUCelularity IncCOM CL A$697.0K–

Sold out since Q4 2021 (11)

Positions held at the end of Q4 2021 that are gone from this filing.

Positions of Affinity Asset Advisors, LLC sold out since Q4 2021
SecurityClassShares in Q4 2021Value in Q4 2021% of portfolio in Q4 2021History
ARNAArena Pharmaceuticals IncCOM NEW100,000$9.29M4.0%History
BBIOBridgeBio Pharma, Inc.COM494,046$8.24M3.5%History
CYTKCytokinetics IncCOM NEW145,552$6.63M2.8%History
ARYDARYA Sciences Acquisition Corp IVCL A400,000$3.97M1.7%History
SNDXSyndax Pharmaceuticals IncCOM175,000$3.83M1.6%History
Environmental Impact Acqu Co29408N106COM CL A300,000$2.98M1.3%–
MRTXMirati Therapeutics, Inc.COM20,000$2.93M1.3%History
PRCTPROCEPT BioRobotics CorpCOM100,000$2.50M1.1%History
NTLAIntellia Therapeutics, Inc.COM10,000$1.18M0.5%History
ALDXAldeyra Therapeutics, Inc.COM100,759$403.0K0.2%History
IOVAIovance Biotherapeutics, Inc.COM20,000$382.0K0.2%History